AbCellera Expands Multi-Target Antibody Discovery Collaboration With Regeneron
Portfolio Pulse from Benzinga Newsdesk
AbCellera (ABCL) has expanded its multi-target collaboration with Regeneron (REGN) to discover therapeutic antibodies for up to eight targets, increased from the original four. The collaboration, which began in March 2020, leverages AbCellera's antibody discovery engine and Regeneron's VelocImmune® mice to identify novel therapeutic antibodies. Regeneron has the right to develop and commercialize therapeutic antibodies resulting from the collaboration, while AbCellera receives research payments and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of products.
September 20, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbCellera's expanded collaboration with Regeneron could lead to increased research payments and potential downstream clinical and regulatory milestone payments and royalties.
The expanded collaboration with Regeneron increases the potential for AbCellera to receive more research payments and potential downstream clinical and regulatory milestone payments and royalties. This could positively impact AbCellera's revenue and profitability in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Regeneron's expanded collaboration with AbCellera could lead to the discovery of more therapeutic antibodies, strengthening its preclinical portfolio.
The expanded collaboration with AbCellera increases the potential for Regeneron to discover more therapeutic antibodies, which could strengthen its preclinical portfolio and lead to the development of new products. This could positively impact Regeneron's future revenue and profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100